^
    Contact us  to learn more about
    our Premium Content:  News alerts, weekly reports and conference planners
    DRUG:

    ITI-1001

    i
    Other names: ITI-1001
    Associations

    News

    Trials
    Company:
    HLB Bio Group
    Drug class:
    Immunostimulant
    Related drugs:
    Associations

    News

    Trials
    2ms
    Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1, N=10, Active, not recruiting, Immunomic Therapeutics, Inc. | Trial primary completion date: Jun 2025 --> Mar 2026 | Recruiting --> Active, not recruiting
    Enrollment closed • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • FOXP3 (Forkhead Box P3)
    |
    ITI-1001
    4ms
    Study to Evaluate the Safety, Tolerability, Immunogenicity and Preliminary Efficacy of ITI-1001 In Patients With Newly Diagnosed Glioblastoma (GBM) (clinicaltrials.gov)
    P1, N=10, Recruiting, Immunomic Therapeutics, Inc.
    Trial completion date • Trial primary completion date
    |
    CD8 (cluster of differentiation 8) • CD163 (CD163 Molecule) • FOXP3 (Forkhead Box P3)
    |
    ITI-1001
    almost2years
    Development and Characterization of an HCMV Multi-Antigen Therapeutic Vaccine for Glioblastoma Using the UNITE Platform. (PubMed, Front Oncol)
    Further characterization of these two groups showed high infiltration of CD3+, CD4+, and CD8+ T cells in responders compared to non-responders. Thus, we show that vaccination with HCMV antigens using the ITI-1001-UNITE platform generates strong cellular and humoral immune responses, triggering significant antitumor activity, leading to enhanced survival in a mouse model of GBM.
    Journal
    |
    CD8 (cluster of differentiation 8) • IFNG (Interferon, gamma) • CD4 (CD4 Molecule) • LAMP1 (Lysosomal Associated Membrane Protein 1)
    |
    ITI-1001